title: Sensitivities of human glioma cell lines to interferons and double-stranded RNAs individually and in synergistic combinations.
abstract: The antiproliferative effects of human interferons (IFNs) and double-stranded RNAs (dsRNAs) were studied in five human glioma cell lines. Dose response curves were generated over a 72 hour treatment period. The concentration of interferon or double-stranded RNA necessary to produce a 50% antiproliferative response (GI50) was calculated by linear regression analysis. Two cell lines were more sensitive to IFN-beta than to IFN-alpha, one cell line was more sensitive to IFN-alpha than to IFN-beta and two cell lines had approximately equal sensitivities to both interferons. All cell lines showed some sensitivity to either IFN-alpha or IFN-beta. IFN-gamma had no antiproliferative effect on any of the cell lines. In addition, only one of the cell lines displayed sensitivity to dsRNA, in which the response to poly(I).poly(C) was greater than that to a mismatched analogue of poly(I).poly(C), r(I)n.r(C12,U)n (Ampligen). There was no correlation between the sensitivities to type I IFNs (alpha and beta), type II IFN (gamma) or the dsRNAs. The antiproliferative effect of combinations of IFNs, or IFNs and Ampligen, was studied in one of the cell lines. A significant synergistic antitumor effect was seen with all of the IFN/Ampligen combinations (p less than 0.02), including IFN-gamma/Ampligen, even though these cells were resistant to IFN-gamma alone. Synergy was also seen in the IFN-alpha/IFN-gamma (p less than 0.02) and IFN-beta/IFN-gamma (p less than 0.05) combinations. The IFN-alpha/IFN-beta combination gave an additive antitumor effect. These results indicate that IFN-alpha and IFN-beta alone or combinations of type I IFNs, type II IFNs and Ampligen can be effective in inhibiting the growth of glioma cells.
mesh_terms: D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D004338:Drug Combinations; D005910:Glioma; D006801:Humans; D007372:Interferons / Q000494:pharmacology*; D011066:Poly C / Q000494:pharmacology; D011069:Poly I / Q000494:pharmacology; D011070:Poly I-C; D011072:Poly U; D011131:Polyribonucleotides / Q000494:pharmacology; D012330:RNA, Double-Stranded / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects*
chemical_list: D004338:Drug Combinations; D011131:Polyribonucleotides; D012330:RNA, Double-Stranded; D011069:Poly I; D011072:Poly U; D011066:Poly C; D007372:Interferons; C047490:poly(I).poly(c12,U); D011070:Poly I-C